Abstract:28 Background: Neoantigen vaccine is an emerging modality to treat cancer by unleashing cytotoxic T cells against tumor-specific mutant antigens. Neoantigens are de-novo changes in tumor cells and are hence more immunogenic and less susceptible to off-target toxicities. In building our own pipeline for neoantigen discovery, we used the mouse colon adenocarcinoma cell line MC38 as a validation model. Methods: We sequenced MC38 cells by whole exome and RNA sequencing to shortlist variants. Candidates were confirmed by sanger sequencing, then analyzed for binding affinity to MHC class I H2-Kb and H2-Db. We selected top 10 epitopes for facile modification to maximize immunogenicity by taking into account peptide characteristics, such as hydrophobicity. In-vivo immunogenicity was tested by subcutaneous injections of pooled peptides in C57BL/6J mice. Amongst the 10 peptides tested, we picked five that elicited greatest IFNγ secretion in re-stimulated splenocytes. Predicted binding affinity did not correlate with in-vivo immunogenicity. We inoculated MC38 cells into the left flank of C57BL/6J mice and started treatment four days later. Mice were injected twice weekly with PBS (group 1), CpG only (group 2), anti-PDL1 only (group 3), Peptide pool + CpG (group 4) and Peptide pool + CpG + anti-PDL1 (group 5) (n=8 per group). CpG ODN 1826 is a TLR9 agonist and acts as an adjuvant, while anti-PDL1 is an immune checkpoint inhibitor. We monitored tumor size, animal weights and food intake every 2-3 days. Results: In control group 1, tumor size exponentially increased by 36 folds on the 18 th day of treatment. Groups 2, 3, 4 and 5 saw 16, 13, 8 and 5-fold increases in tumor size respectively, 21 days post-treatment. No tumors were found in 3/7 mice in group 5 upon sacrifice, suggesting tumor regression. Tumor control in groups 4 and 5 corroborated with significant IFNγ secretion from neoantigen re-stimulated splenocytes. We observed 38-45 fold expansion in the number of CD8+ KLRG1+ short-lived effector cells and significant increase in PD-1+ TIM3+ exhausted T cells in group 4 and 5 relative to control. Reps1 and Adpgk neoantigen peptides are widely reported and used in MC38 syngenic model. However, they were not included because both were undetected by sequencing. Cell line authentication by STR profiling confirmed that our cells matched that of MC38 from Kerafast. Conclusions: Using an in-house pipeline, we derived a set of novel neoantigen peptides that robustly controlled tumor growth in the MC38 tumor challenge model. In-silico binding predictions did not correlate with in-vivo patterns of IFNγ secretion. In-vivo tests for IFNγ induction after peptide vaccination is a better measure for potential in tumor control. Upregulation of T-cell exhaustion markers after peptide vaccination explains the improved response with anti-PDL1. Reps1 and Adpgk mutations were absent in our cells, which calls caution to researchers conducting similar research.

Prevention of Spontaneous Tumor Development in a Ret Transgenic Mouse Model by Ret Peptide Vaccination with Indoleamine 2,3-Dioxygenase Inhibitor 1-Methyl Tryptophan.

Therapeutic Effect of MIP-1alpha-recruited Dendritic Cells on Preestablished Solid and Metastatic Tumors.

Inhibition of Tumor Angiogenesis in Lung Cancer by T4 Phage Surface Displaying Mvegfr2 Vaccine

All‐Trans‐Retinoic Acid‐Adjuvanted Mrna Vaccine Induces Mucosal Anti‐Tumor Immune Responses for Treating Colorectal Cancer

Anti-metastatic effects of DNA vaccine encoding single-chain trimer composed of MHC I and vascular endothelial growth factor receptor 2 peptide.

Combination of GNRs-PEI/cGAMP-laden Macrophages-Based Photothermal Induced in Situ Tumor Vaccines and Immune Checkpoint Blockade for Synergistic Anti-Tumor Immunotherapy.

Immunotherapy effect on tumor and recombination of VGFR phage vaccine

Linkage between melanocytic tumor development and early burst of Ret protein expression for tolerance induction in metallothionein-I/ ret transgenic mouse lines

Retraction Note: Inhibition of RM-1 Prostate Carcinoma and Eliciting Robust Immune Responses in the Mouse Model by Using VEGF-M 2 -Gnrh 3 -Hinge-mvp Vaccine

RET mutation as a putative prognostic biomarker for immune checkpoint inhibitors therapy in various malignancies

Enhanced Growth of Primary Tumors in Cancer-Prone Mice after Immunization Against the Mutant Region of an Inherited Oncoprotein

1-Methyl-d-tryptophan Reduces Tumor CD133+ Cells, Wnt/β-catenin and NF-κβp65 While Enhances Lymphocytes NF-κβ2, STAT3, and STAT4 Pathways in Murine Pancreatic Adenocarcinoma.

Immunogenicity and Efficacy of a Rationally Designed Vaccine Against Vascular Endothelial Growth Factor in Mouse Solid Tumor Models

Abstract 4106: A novel synthetic long peptide vaccine composition targeting multiple PD-L1 T-cell epitopes exhibits anti-tumor efficacy in a syngeneic mouse colorectal cancer model

An Experiment Study of in Vitro Induced Antitumor Immune Responses by Vaccination of Tumor Lysate-Pulsed Dendritic Cells to Kill SO-RB50

OX40L-expressing Recombinant Modified Vaccinia Virus Ankara Induces Potent Antitumor Immunity Via Reprogramming Tregs

Antitumor Efficacy Induced By A B16f10 Tumor Cell Vaccine Treated With Mitoxantrone Alone Or In Combination With Reserpine And Verapamil In Mice

Novel neoantigen peptides and tumor regression in the MC38 colorectal cancer model.

Vaccination with Transforming Growth Factor-Beta Insensitive Dendritic Cells Suppresses Pulmonary Metastases of Renal Carcinoma in Mice

Preclinical Safety and Biodistribution in Mice Following Single-Dose Intramuscular Inoculation of Tumor DNA Vaccine by Electroporation

Noninvasive Transdermal Administration of mRNA Vaccines Encoding Multivalent Neoantigens Effectively Inhibits Melanoma Growth